SELLAS Life Sciences Group, Inc. (SLS) is a late-stage clinical biopharmaceutical company focused on developing novel cancer immunotherapies. Its lead candidate, galinpepimut-S (GPS), is a peptide-based cancer vaccine that targets the WT1 protein, an antigen expressed across a broad range of hematologic malignancies and solid tumors. GPS is licensed from Memorial Sloan Kettering Cancer Center. The company is also advancing SLS009 (tambiciclib), a selective CDK9 inhibitor being studied in AML patients with unfavorable prognostic features.
SELLAS currently has no approved products and generates no product revenue, funding its operations through equity financings and partnerships. Investors follow the stock primarily as a high-risk, high-reward play on binary clinical data readouts, with its market value tied closely to the regulatory prospects of its pipeline rather than to current financial results. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the last 30 days, SLS has advanced approximately 76%, rising from a closing price of $10.49 on October 19, 2026, to about $18.45 in recent intraday trading. The move was not gradual: the stock spent much of the period drifting lower, reaching roughly $7.47 by mid-November, before a single-session surge of more than 150% on November 17 following the REGAL trial announcement.
Over the trailing quarter, the shares are up roughly 40% from the mid-$13 level reached in mid-August. That broader gain, however, is almost entirely attributable to the November data readout. For most of the quarter, SLS trended sideways to lower, reflecting investor caution ahead of a make-or-break clinical catalyst and the elevated short positioning that accompanied it.
The dominant catalyst was the November 17 announcement of positive topline results from the Phase 3 REGAL trial, which evaluated GPS in AML patients who had achieved a second or later complete remission but were ineligible for stem cell transplantation. The trial met its primary endpoint of overall survival, showing a 41% reduction in the risk of death (hazard ratio of 0.59, p-value of 0.035). Median overall survival was 24.0 months for GPS-treated patients versus 14.7 months for those receiving the best available treatment, with no new safety signals reported.
The readout triggered an extraordinary repricing. Trading volume reached approximately $2.58 billion on November 17, and the stock briefly triggered exchange-level volatility pauses. Because short interest stood at roughly 28% of the float, with about 57.1 million shares shorted as of late October, the rally was reinforced by short covering.
The move moderated after the company announced a $150 million underwritten public offering, with J.P. Morgan and TD Cowen as joint book-running managers, prompting dilution concerns in after-hours trading. Separately, SELLAS reported third-quarter results on November 12, posting a loss per share of $0.05 that matched consensus, alongside a net loss of $10.1 million for the quarter. Maxim analyst Jason McCarthy maintained a Buy rating and a $30 price target following the data.
For much of the trailing three months, SLS was defined by anticipation and uncertainty rather than fundamental news. The REGAL trial reached its pre-specified event threshold in October, triggering the final overall survival analysis, and the company guided that topline results were expected in November. Ahead of the readout, the shares weakened as investors weighed the open-label design and the binary risk of the outcome, while short interest remained elevated near 29% of the float.
Broader sentiment in the cancer-vaccine space was supportive, with continued investor interest in immunotherapies across the sector. The positive REGAL results ultimately validated the thesis for GPS and compressed much of the quarter's repricing into a single session, underscoring how heavily the stock's trajectory has depended on a concentrated set of clinical milestones.
The most important near-term catalyst is the regulatory path for GPS. SELLAS has said it plans to meet with the FDA to discuss its filing strategy and is preparing a BLA submission for the first half of 2027. Additional details from the REGAL trial are expected at an upcoming medical conference, which could refine the market's view of the therapy's profile.
Investors should also monitor the SLS009 program, including preliminary Phase 2 results in newly diagnosed AML expected before year-end and data presented at the American Society of Hematology meeting. Financially, the $150 million offering will dilute existing shareholders but is intended to strengthen the balance sheet, which held approximately $134.7 million in cash at the end of September. Regulatory decisions, competitive developments in AML treatment, and the company's continued funding needs remain central risk factors.
For traders looking to track momentum and identify potential opportunities across thousands of securities, Tickeron's Trending AI Robots page provides a curated view of the platform's most relevant automated trading systems. Tickeron offers hundreds of AI-driven trading bots that trade thousands of tickers, but only the top-performing and most relevant bots are featured in this section. These bots vary in strategy, timeframe, and performance metrics, allowing users to compare approaches rather than relying on a single method. The page is designed to help investors observe how data-driven systems are positioned as market conditions evolve. I find it useful to cross-reference my own analysis with these automated signals from time to time.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
SLS broke above its upper Bollinger Band on November 17, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 53 similar instances where the stock broke above the upper band. In 47 of the 53 cases the stock fell afterwards. This puts the odds of success at 89%.
The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where SLS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
The Aroon Indicator for SLS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 52 of 60 cases where SLS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on SLS as a result. In 79 of 87 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for SLS just turned positive on November 17, 2026. Looking at past instances where SLS's MACD turned positive, the stock continued to rise in 36 of 41 cases over the following month. The odds of a continued upward trend are 88%.
SLS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +8.88% 3-day Advance, the price is estimated to grow further. Considering data from situations where SLS advanced for three days, in 240 of 275 cases, the price rose further within the following month. The odds of a continued upward trend are 87%.
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (12.352) is normal, around the industry mean (3.592). P/E Ratio (-38.273) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (442.120).
The Tickeron PE Growth Rating for this company is 14 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. SLS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of biopharmaceuticals
Industry Biotechnology